Please login to the form below
anaesthetics
This page shows the latest anaesthetics news and features for those working in and with pharma, biotech and healthcare.
Sandoz expands into Japan with €400m Aspen deal
Aspen’s portfolio consists of approximately 20 off-patent medicines, including anaesthetics like Xylocaine and speciality brands such as immune suppressing drug Imuran for multiple sclerosis patients.
Latest news
-
Stung by critics, J&J says antidepressant Spravato saves money
It is a single isomer form of ketamine, a low-cost anaesthetic, and ICER says the similarity between the two drugs “raises issues for all stakeholders about how to consider
-
J&J’s Spravato breaks depression drought at FDA
The green light for nasal spray formulation of esketamine – a derivative of the anaesthetic ketamine – is for use of the drug as an add-on to oral antidepressants in people with
-
Gyroscope's gene therapy given to first dry AMD patient
GT005 was administered under a local anaesthetic by Robert MacLaren, an ophthalmology specialist at Oxford Eye Hospital.
-
FDA panel backs J&J’s new-class antidepressant
The nasal spray formulation of esketamine – a derivative of the anaesthetic ketamine that has the proposed name Spravato – was backed by a 14-2 vote by an FDA advisory committee yesterday
-
AcelRX’s potent opioid tablets set to win FDA backing for pain relief
Evaluating the safety and effectiveness of products for use in anaesthesiology and surgery, the Anaesthetic and Analgesic Drug Products Advisory Committee voted 10 to 3 in favour of the drug.
More from news
Approximately 1 fully matching, plus 26 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2016
200+. Janssen / J&J (US). Piramal (IN). Asset acquisition. 5 injectable pain / anaesthetic products.
-
Deal Watch September 2016
500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva, Nimbex, Tracrium, Mivacron and Anectinein – excludes US/CA rights].
-
Deal Watch June 2016
Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and
-
Pharma deals in June 2015
Neosaxitoxin, novel anaesthetic for local anaesthesia and post-op pain management. Collaboration, licence.
-
Pharma deals during March 2014
Baxter's medical products business has annual sales of over $9bn and a portfolio of intravenous solutions and nutritional therapies, drug delivery systems, premixed and other injectable drugs, inhalation anaesthetics and
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
It’s all about patient outcomes… right?
general anaesthetic. ... Routledge; London, UK, 2002. Snow SJ. Blessed Days of Anaesthesia: How Anaesthetics Changed the World.
-
"Legal highs" ruling leaves illegal labs laughing
These include the anaesthetic nitrous oxide, or laughing gas. . N2O has been used as a recreational drug since 1799, when 'laughing gas parties' were popular among the ruling classes.
-
Healthcare 2025: what the future holds for pharma
This was led by major advances in three core areas:. Health: Access to innovative medicines, surgery and anaesthetics, clean air and water.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
-
Vice President
-
Competitive Salary Offered
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Consultant
-
competitive salary
- Account Director or Senior Account Director
-
Salary TBC
Subscribe to our email news alerts
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- Moving annual total (MAT)
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- Sanofi completes acquisition of immuno-oncology specialist Synthorx
- Roche’s SMA treatment risdiplam hits another clinical target
- Lilly will aim for one $1bn-$5bn deal per quarter in 2020
- WHITE PAPER: Marketing fulfilment – a balancing act
- AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer
- Roche files Tecentriq/Avastin combo in liver cancer
- New coronavirus sees drug developers scramble to develop a vaccine
- The balancing act that’s keeping pharma and biotech market access on its toes
- Boris Johnson to unveil ‘talent visa’ for high-flying scientists
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- The balancing act that’s keeping pharma and biotech market access on its toes
- Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
- Tackling antimicrobial resistance on multiple fronts
- An urgent change of direction is needed in how we respond to AMR...
- Happy Chinese New Year 2020 - The Year of The Rat
- A fond farewell to The Year of the Pig...
Quick links
Infographics
